AphioTx is excited to announce we have been chosen to advance to the top 10 at Start Up TNT’s Life Sciences Investment Summit. Watch the recording of our pitch that landed us the next spot in the summit.
Over a 15-year period, key scientific discoveries were made that changed our understanding of the important roles pannexin-1 channels play in opioid withdrawal, chronic pain, stroke, and cognitive impairment. These discoveries were led by three researchers from the Hotchkiss Brain Institute at the University of Calgary: Drs. Tuan Trang, Roger Thompson, and Darren Derksen.
Researchers out of the Hotchkiss Brain Institute at the University of Calgary have discovered a treatment that shows potential in alleviating opioid withdrawal symptoms, which can help break the cycle of opioid use for millions worldwide. Join our leading scientist Dr. Tuan Trang and other scientific, medical and mental health and addictions experts for this community-run webinar with the Hotchkiss Brain Institute discussing the potential of this research, what this means for communities worldwide, and plans to fuel the development of the science from bench to bedside.
Governments across North America are taking urgent action to address the growing opioid crisis that is drastically gaining momentum. Current interventions have proven to be ineffective when trying to manage the growing overdose numbers and the number of patients experiencing debilitating withdrawal symptoms. We have compiled the latest articles on the subject, contextualizing the crisis, and emphasizing the global need for innovative treatments to help patients. AphioTx is eager to fill the need for effective therapies to help patients overcome their withdrawal symptoms and break the cycle of opioid use. Overdose Deaths Read more…
Calgary-based Company Launches with Potential Innovative Treatment to Help Tackle Global Opioid Crisis
AphioTx, a clinical research company from the University of Calgary developing a potential treatment for opioid withdrawal, is pleased to announce its formal launch today.
The CIHR Project Grant program chose projects led by Drs. Sabine Gilch, PhD, Tuan Trang, PhD, and Patrick Whelan, PhD, all researchers in the University of Calgary Faculty of Veterinary Medicine (UCVM).
Opioid use and abuse is a significant social, health and economic issue in Canada. Researchers at the University of Calgary’s Faculty of Veterinary Medicine (UCVM) and Hotchkiss Brain Institute (HBI) at the Cumming School of Medicine (CSM) have discovered that an existing anti-gout medication is effective in reducing the severity of withdrawal symptoms in opioid-dependent rodents.
Researchers at the University of Alberta have developed a new method of controlling biology at the cellular level using light.
The opium poppy is a natural source of opioids such as morphine. Although they are revered for their potent pain-relieving effects, when used chronically, opioids can lead to analgesic tolerance, hyperalgesia and withdrawal. Burma et al. (p 355) show that pannexin-1 (Panx1) channels on spinal microglia are essential for opioid withdrawal, and that blocking Panx1 can alleviate opioid withdrawal in rodents. Puig and Gutstein (p 272) discuss these findings alongside those recently reported by Corder et al. in the February issue of Nature Medicine. Read more…
Opioids are the mainstay of treatment strategies to reduce pain, but withdrawal can be a serious problem when patients stop taking these drugs. However, beyond the recognition that microglia play a role in this phenomenon, little is known about the cellular mechanisms involved. Now, new research shows how microglia contribute to withdrawal in rodents and identifies a potential path toward easing withdrawal in patients.